PT - JOURNAL ARTICLE AU - Asaf Maoz AU - Carter Merenstein AU - Yusuke Koga AU - Austin Potter AU - Adam C. Gower AU - Gang Liu AU - Sherry Zhang AU - Hanqiao Liu AU - Christopher Stevenson AU - Avrum Spira AU - Mary E. Reid AU - Joshua D. Campbell AU - Sarah A. Mazzilli AU - Marc E. Lenburg AU - Jennifer E. Beane TI - Elevated T cell repertoire diversity is associated with progression of lung squamous cell premalignant lesions AID - 10.1101/2021.02.25.21252467 DP - 2021 Jan 01 TA - medRxiv PG - 2021.02.25.21252467 4099 - http://medrxiv.org/content/early/2021/03/03/2021.02.25.21252467.short 4100 - http://medrxiv.org/content/early/2021/03/03/2021.02.25.21252467.full AB - Objective The immune response to invasive carcinoma has been the focus of published work, but little is known about the adaptive immune response to bronchial premalignant lesions (PMLs), precursors of lung squamous cell carcinoma. This study was designed to characterize the T cell receptor (TCR) repertoire in PMLs and its association with clinical, pathological, and molecular features.Methods Endobronchial biopsies (n=295) and brushings (n=137) from high-risk subjects (n=50), undergoing lung cancer screening at approximately 1-year intervals via autofluorescence bronchoscopy and CT, were profiled by RNA-seq. We applied the TCR Repertoire Utilities for Solid Tissue/Tumor (TRUST) tool to the RNA-seq data to identify TCR CDR3 sequences across all samples. In the biopsies, we measured the correlation of TCR diversity with previously derived immune-associated PML transcriptional signatures and outcome. We also quantified the spatial and temporal distribution of shared and clonally expanded TCRs. Using the biopsies and brushes, the ratio of private (i.e., found in one patient only) and public (i.e., found in two or more patients) TCRs was quantified and the CDR3 sequences were compared to those found in curated databases with known antigen specificities.Results We detected 39,303 unique TCR sequences across all samples. In PML biopsies, TCR diversity was negatively associated with a transcriptional signature of T-cell mediated immune activation (Spearman’s rho −0.34, p < 0.001) associated with PML outcome.Additionally, in lesions of the proliferative molecular subtype, TCR diversity was decreased in regressive versus progressive/persistent PMLs (p=0.045). Within each patient, TCRs were more likely to be shared between biopsies sampled at the same timepoint than biopsies sampled at the same anatomic location at different times. Clonally expanded TCRs, within a biopsied lesion, were more likely to be expanded at future time points than non-expanded clones. The majority of TCR sequences were found in a single sample, with only 3,396 (8.6%) found in more than one sample and 1,057 (2.7%) found in two or more patients (i.e. public), however, when compared to a public database of CDR3 sequences, 4,543 (11.6%) of TCRs were identified as public. TCRs with known antigen specificities were enriched among Public TCRs (p < 0.001).Conclusions Decreased TCR diversity may reflect nascent immune responses that contribute to PML elimination. Further studies are needed to explore the potential for immunoprevention of PMLs.Competing Interest StatementJEB, SAM, JDC, MER, AES and MEL received commercial research grants from Janssen Pharmaceuticals. MEL is a consultant to Veracyte. AES and CS are employed by Johnson and Johnson. Funding StatementThis study was supported by funding from Janssen Research and Development (PIs: JEB, SAM, JDC) and by a Stand Up To Cancer-LUNGevity-American Lung Association Lung Cancer Interception Dream Team Translational Cancer Research Grant (grant number: SU2C-AACR-DT23-17 to S.M. Dubinett and A.E. Spira). Stand Up To Cancer is a division of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, the scientific partner of SU2C.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Boards at Boston University Medical Center and Roswell Comprehensive Cancer Center approved the study and all subjects provided written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRNA sequencing data from human endobronchial biopsies and brushings has been previously deposited in the NCBI Gene Expression Omnibus under accession code GSE109743. http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109743 PMLpremalignant lesionCPKclonotypes per kilobaseTCRT cell receptorPCGAPre-Cancer Genome Atlas